Recently, at the SIA 2025 Scientific Skincare Innovation Alliance Annual Conference, grandly held in Shanghai from November 27‑29, 2025, the highly‑anticipated SIA100 Annual Scientific Products & Technical Achievement awards were officially announced. Following a rigorous expert review process, Dieckmann was honored with the SIA100 2025 Annual Technology Achievement Award for its independently developed New Biomimetic C46 Ceramide EOS.

This new biomimetic C46 Ceramide EOS marks Dieckmann's second innovative ceramide to feature compound and application patent filings. It has successfully obtained NMPA filing as a new cosmetic raw material (Filing No.: NMPA New Cosmetic Raw Material 20250067), filling the application gap of Ceramide EOS within China's cosmetic industry. Dieckmann has now achieved commercial-scale production of this ingredient, making this high-value component accessible to consumer products and offering a novel active ingredient option for addressing skin health concerns.

Dieckmann Ceramide EOS features a C46 biomimetic ultra-long carbon chain that precisely matches the natural structural profile of human skin, perfectly aligning with the highest abundance distribution of native ceramides in the epidermis. Manufactured using green synthesis technology, it boasts a Natural Origin Index of 1, meeting the demands of clean beauty formulations. Furthermore, Dieckmann's proprietary process significantly reduces production costs, making cutting-edge repair technology truly affordable and accessible.

In-vivo efficacy studies have validated its multifunctional performance. Beyond exceptional moisturizing, soothing, and repairing capabilities, Dieckmann Ceramide EOS demonstrates particularly notable anti-itch and analgesic benefits:

• At a concentration of 31.25 PPM, it inhibits histamine release and upregulates the expression of antimicrobial peptide human β-defensin 2 by 129.24%.

• At 0.025%, it suppresses TRPV-1 (capsaicin receptor) expression by 34%.

These properties make it highly suitable for a range of demanding applications, including post-procedure recovery following aesthetic treatments, sensitive skin soothing, and anti-aging synergy.

Notably, this year's conference also unveiled the inaugural "Future 100 – Skin Health Future Top 100 Enterprise List." For the first time, this list precisely focuses on the industry's "mid-tier powerhouses" and "hidden champions," selecting the most promising growth-oriented enterprises through a combination of authoritative expert evaluation and market performance assessment. Dieckmann distinguished itself with its robust technological innovation capabilities and outstanding growth trajectory, earning a place on the "Future 100 – Skin Health Top 100 Enterprises" list. This recognition positions Dieckmann as a representative of enterprises that have successfully achieved deep integration of innovation and high-impact growth.

These dual accolades represent significant recognition from the SIA Scientific Skincare Innovation Alliance and industry experts of Dieckmann Biotechnology's unwavering commitment to independent innovation and deep-rooted expertise in the ceramide field. Looking ahead, Dieckmann Biotechnology will continue to intensify R&D investment, deepen collaborative partnerships across industry, academia, research, and medical institutions in the skin health sector, and strive to translate innovative technological achievements into superior products and solutions for global partners.